<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075413</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000346365</org_study_id>
    <secondary_id>UTMB-02403</secondary_id>
    <nct_id>NCT00075413</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A Pilot Phase II Protocol Of Arsenic Trioxide (TRISENOX) In Subjects With Advanced Carcinoma Of The Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, use different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well arsenic trioxide works in treating women&#xD;
      with locally advanced or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and activity of arsenic trioxide in women with locally advanced or&#xD;
           metastatic breast cancer.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response, in terms of objective tumor response and response duration, in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Determine the patterns of failure and survival in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive arsenic trioxide IV over 1-2 hours on days 1-5 of week 1 and on days 1 and 5&#xD;
      of weeks 2-8 (for course 1 only). Beginning with course 2 and for all subsequent courses,&#xD;
      patients receive arsenic trioxide on days 1 and 5 of weeks 1-8. Treatment repeats every 8&#xD;
      weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who have a complete response (CR) receive an additional course beyond documentation&#xD;
      of CR. Patients who have a CR due to local consolidative therapy (e.g., surgery or&#xD;
      radiotherapy) receive an additional 2 courses beyond CR.&#xD;
&#xD;
      Patients are followed for 1 month, every 3 months for 2 years, every 6 months for 3 years,&#xD;
      and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 9-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to identify qualified subjects willing to participate in this study&#xD;
  </why_stopped>
  <start_date>November 2002</start_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Locally advanced disease&#xD;
&#xD;
                    -  Cannot be adequately treated by radiotherapy or surgery&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Ineligible for OR received prior anthracycline- and/or taxane-based chemotherapy with&#xD;
             subsequent disease progression&#xD;
&#xD;
          -  No uncontrolled Central Nervous System (CNS) metastases&#xD;
&#xD;
          -  Ineligible for treatment protocols of higher priority&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-1 OR&#xD;
&#xD;
          -  Southwest Oncology Group (SWOG) 0-1 OR&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  Serum Glutamic Oxalacetic Transaminase (SGOT)/Serum Glutamic Pyruvic Transaminase&#xD;
             (SGPT) no greater than 3 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Calcium no greater than 12 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac ejection fraction greater than 50%&#xD;
&#xD;
          -  No myocardial infarction or ischemia within the past 6 months&#xD;
&#xD;
          -  No uncontrolled clinically significant dysrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Electrolytes normal&#xD;
&#xD;
          -  Magnesium normal&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior or ongoing grade 2-4 peripheral neuropathy&#xD;
&#xD;
          -  No comorbid condition that would render the patient at high risk from study treatment&#xD;
             complications&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent cytokine therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens for breast cancer&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to an indicator lesion unless there is objective evidence of&#xD;
             tumor growth in that lesion&#xD;
&#xD;
          -  No concurrent radiotherapy except for the following:&#xD;
&#xD;
               -  Palliative or emergent radiotherapy&#xD;
&#xD;
               -  Local consolidative radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 2 weeks since prior surgery&#xD;
&#xD;
          -  Concurrent local consolidative surgery allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior antineoplastic agents for nonmalignant conditions (e.g.,&#xD;
             methotrexate for rheumatoid arthritis)&#xD;
&#xD;
          -  No concurrent antineoplastic agents for nonmalignant conditions&#xD;
&#xD;
          -  No concurrent participation in another treatment protocol&#xD;
&#xD;
          -  Concurrent local palliative therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennie V. Jones, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

